Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma

Sanjiv Sur, P. Bouchard, D. Holbert, M. R. Van Scott

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The worldwide incidence, prevalence, and fatality rates from asthma are increasing despite currently available therapeutic modalities. Systemic administration of interleukin (IL)-12 has been shown to inhibit airway reactivity in murine models of asthma, but the required dosage is high and may be toxic. This study tested the hypothesis that IL-12 administered directly into the lungs is more effective in inhibiting airway reactivity than systemically administered IL-12, allowing lower doses to be used. A low dose (10 ng) of IL-12 was delivered either intratracheally (mucosal delivery) or intraperitoneally (systemic delivery) at the time of ragweed (RW) challenge in mice sensitized to RW. Basal airway resistance and airway reactivity to methacholine were measured 3 days after RW challenge. Compared to phosphate-buffered saline (PBS) challenge of RW sensitized mice, RW challenge increased basal resistance and the slope of the methacholine dose-response curve. Methacholine challenge of RW-challenged mice also induced premature respiratory failure (respiratory rate < 150/min, tidal volume < 0.15 mL) in some animals. Administration of mucosal or systemic IL-12 at the time of RW challenge decreased basal airway resistance. However, only mucosal IL-12 decreased airway reactivity and inhibited respiratory failure during methacholine challenge. These findings indicate that mucosal delivery of a low dose of IL-12 is more effective than systemic IL-12 in inhibiting airway reactivity and respiratory failure in a mouse model of asthma.

Original languageEnglish (US)
Pages (from-to)477-489
Number of pages13
JournalExperimental Lung Research
Volume26
Issue number6
StatePublished - 2000

Fingerprint

Methacholine Chloride
Ambrosia
Interleukin-12
Respiratory Insufficiency
Asthma
Airway Resistance
Mucosal Administration
Poisons
Tidal Volume
Respiratory Rate
Animals
Phosphates
Lung
Incidence

Keywords

  • Airway reactivity
  • Asthma
  • Respiratory failure

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Sur, S., Bouchard, P., Holbert, D., & Van Scott, M. R. (2000). Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma. Experimental Lung Research, 26(6), 477-489.

Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma. / Sur, Sanjiv; Bouchard, P.; Holbert, D.; Van Scott, M. R.

In: Experimental Lung Research, Vol. 26, No. 6, 2000, p. 477-489.

Research output: Contribution to journalArticle

Sur, S, Bouchard, P, Holbert, D & Van Scott, MR 2000, 'Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma', Experimental Lung Research, vol. 26, no. 6, pp. 477-489.
Sur, Sanjiv ; Bouchard, P. ; Holbert, D. ; Van Scott, M. R. / Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma. In: Experimental Lung Research. 2000 ; Vol. 26, No. 6. pp. 477-489.
@article{ed6aed1a13894c0cb8c95454d74c94f2,
title = "Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma",
abstract = "The worldwide incidence, prevalence, and fatality rates from asthma are increasing despite currently available therapeutic modalities. Systemic administration of interleukin (IL)-12 has been shown to inhibit airway reactivity in murine models of asthma, but the required dosage is high and may be toxic. This study tested the hypothesis that IL-12 administered directly into the lungs is more effective in inhibiting airway reactivity than systemically administered IL-12, allowing lower doses to be used. A low dose (10 ng) of IL-12 was delivered either intratracheally (mucosal delivery) or intraperitoneally (systemic delivery) at the time of ragweed (RW) challenge in mice sensitized to RW. Basal airway resistance and airway reactivity to methacholine were measured 3 days after RW challenge. Compared to phosphate-buffered saline (PBS) challenge of RW sensitized mice, RW challenge increased basal resistance and the slope of the methacholine dose-response curve. Methacholine challenge of RW-challenged mice also induced premature respiratory failure (respiratory rate < 150/min, tidal volume < 0.15 mL) in some animals. Administration of mucosal or systemic IL-12 at the time of RW challenge decreased basal airway resistance. However, only mucosal IL-12 decreased airway reactivity and inhibited respiratory failure during methacholine challenge. These findings indicate that mucosal delivery of a low dose of IL-12 is more effective than systemic IL-12 in inhibiting airway reactivity and respiratory failure in a mouse model of asthma.",
keywords = "Airway reactivity, Asthma, Respiratory failure",
author = "Sanjiv Sur and P. Bouchard and D. Holbert and {Van Scott}, {M. R.}",
year = "2000",
language = "English (US)",
volume = "26",
pages = "477--489",
journal = "Experimental Lung Research",
issn = "0190-2148",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma

AU - Sur, Sanjiv

AU - Bouchard, P.

AU - Holbert, D.

AU - Van Scott, M. R.

PY - 2000

Y1 - 2000

N2 - The worldwide incidence, prevalence, and fatality rates from asthma are increasing despite currently available therapeutic modalities. Systemic administration of interleukin (IL)-12 has been shown to inhibit airway reactivity in murine models of asthma, but the required dosage is high and may be toxic. This study tested the hypothesis that IL-12 administered directly into the lungs is more effective in inhibiting airway reactivity than systemically administered IL-12, allowing lower doses to be used. A low dose (10 ng) of IL-12 was delivered either intratracheally (mucosal delivery) or intraperitoneally (systemic delivery) at the time of ragweed (RW) challenge in mice sensitized to RW. Basal airway resistance and airway reactivity to methacholine were measured 3 days after RW challenge. Compared to phosphate-buffered saline (PBS) challenge of RW sensitized mice, RW challenge increased basal resistance and the slope of the methacholine dose-response curve. Methacholine challenge of RW-challenged mice also induced premature respiratory failure (respiratory rate < 150/min, tidal volume < 0.15 mL) in some animals. Administration of mucosal or systemic IL-12 at the time of RW challenge decreased basal airway resistance. However, only mucosal IL-12 decreased airway reactivity and inhibited respiratory failure during methacholine challenge. These findings indicate that mucosal delivery of a low dose of IL-12 is more effective than systemic IL-12 in inhibiting airway reactivity and respiratory failure in a mouse model of asthma.

AB - The worldwide incidence, prevalence, and fatality rates from asthma are increasing despite currently available therapeutic modalities. Systemic administration of interleukin (IL)-12 has been shown to inhibit airway reactivity in murine models of asthma, but the required dosage is high and may be toxic. This study tested the hypothesis that IL-12 administered directly into the lungs is more effective in inhibiting airway reactivity than systemically administered IL-12, allowing lower doses to be used. A low dose (10 ng) of IL-12 was delivered either intratracheally (mucosal delivery) or intraperitoneally (systemic delivery) at the time of ragweed (RW) challenge in mice sensitized to RW. Basal airway resistance and airway reactivity to methacholine were measured 3 days after RW challenge. Compared to phosphate-buffered saline (PBS) challenge of RW sensitized mice, RW challenge increased basal resistance and the slope of the methacholine dose-response curve. Methacholine challenge of RW-challenged mice also induced premature respiratory failure (respiratory rate < 150/min, tidal volume < 0.15 mL) in some animals. Administration of mucosal or systemic IL-12 at the time of RW challenge decreased basal airway resistance. However, only mucosal IL-12 decreased airway reactivity and inhibited respiratory failure during methacholine challenge. These findings indicate that mucosal delivery of a low dose of IL-12 is more effective than systemic IL-12 in inhibiting airway reactivity and respiratory failure in a mouse model of asthma.

KW - Airway reactivity

KW - Asthma

KW - Respiratory failure

UR - http://www.scopus.com/inward/record.url?scp=0033802436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033802436&partnerID=8YFLogxK

M3 - Article

C2 - 11033769

AN - SCOPUS:0033802436

VL - 26

SP - 477

EP - 489

JO - Experimental Lung Research

JF - Experimental Lung Research

SN - 0190-2148

IS - 6

ER -